Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials

Diabetes, Obesity and Metabolism

Volumn 20, Issue 7, 2018, Pages 1755-1761

  Yamada, Tomohide ^a   Shojima, Nobuhiro ^a   Noma, Hisashi ^b   Yamauchi, Toshimasa ^a   Kadowaki, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

Author keywords

meta analysis; sodium glucose co transporter 2 inhibitor; type 1 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; METABOLISM; ODDS RATIO; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DRUG THERAPY, COMBINATION; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TRACT INFECTIONS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85044312952     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13260     Document Type: Article

References (31)

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034-2054.
2. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971-978. https://doi.org/10.2337/dc15-0078.
3. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-419.
4. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. https://doi.org/10.1056/NEJMoa1611925.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
6. Shamseer L, Moher D, Clarke M, et al. PRISMA-P GroupPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
7. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011. http://handbook.cochrane.org/. Accessed September 1, 2017.
8. White IR. Multivariate random-effects meta-analysis. Stata J. 2009;9:40-56.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
11. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
13. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:529.
14. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258-2265.
15. Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of Canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017;40(2):171-180.
16. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39(4):532-538.
17. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181-1188.
18. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412-419.
19. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017;19(6):814-821.
20. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17(10):928-935.
21. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2016;101(9):3506-3515.
22. Bode BW, Banks P, Sawhney S, Strumph P; The Sotagliflozin JDRF Study Writing Group. 12-Week efficacy and safety of Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study) [Abstract]. Presented at American Diabetes Association 77rd Scientific Session; June 9-13, 2017; San Diego, CA. Abstract no. 147-LB.
23. Buse JB, Garg SK, Rosenstock J, Banks P, Sawhney S, Strumph P; The Sotagliflozin inTandem1 writing group. Twenty-four-week efficacy and safety of Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem1) [Abstract]. Presented at American Diabetes Association 77rd Scientific Session; June 9-13, 2017; San Diego, CA. Abstract no. 60-OR.
24. Danne T, Cariou B, Banks P, Sawhney S, Strumph P; The Sotagliflozin in Tandem2 Writing Group. 24-Week efficacy and safety of Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2) [Abstract]. Presented at American Diabetes Association 77rd Scientific Session; June 9-13, 2017; San Diego, CA. Abstract no. 146-LB.
25. Baker C, Wason S, Banks P, Sawhney S, Strumph P; The Sotagliflozin inTandem4 writing group. 12-Week dose-ranging study of Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4) [Abstract]. Presented at American Diabetes Association 77rd Scientific Session; June 9-13, 2017; San Diego, CA. Abstract no. 70-OR.
26. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337-2348. https://doi.org/10.1056/NEJMoa1708337.
27. Dandona P, Mathieu C, Phillip M, et al. DEPICT-1 InvestigatorsEfficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864-876. https://doi.org/10.1016/S2213-8587(17)30308-X.
28. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
29. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34(10):2237-2243.
30. Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7:44128.
31. Yang Y, Chen S, Pan H, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6944.